Black Diamond Therapeutics (BDTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, Shannon Campbell and Kapil Dhingra, both recommended by the board for approval.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers, with a board recommendation to vote in favor.
Advisory vote on the preferred frequency of future say-on-pay votes, with a recommendation for an annual (1 year) frequency.
Board will consider any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two Class III directors at the 2026 annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, with board support for approval.
Shareholders are asked to indicate preferred frequency for future say-on-pay votes, with a recommendation for annual votes.
Latest events from Black Diamond Therapeutics
- Annual meeting covers director elections, auditor ratification, pay, and ESG oversight.BDTX
Proxy filing29 Apr 2026 - Strong clinical and financial performance, with silevertinib advancing and cash runway to 2028.BDTX
Q4 202516 Mar 2026 - Silevertinib demonstrates robust efficacy in NSCLC and is advancing to pivotal GBM trials.BDTX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - BDTX-1535 achieved 42% ORR and durable responses in resistant EGFRm NSCLC at 200 mg.BDTX
Study Update20 Jan 2026 - BDTX-1535 shows strong efficacy and safety in NSCLC, with pivotal data expected in 2025.BDTX
Stifel 2024 Healthcare Conference13 Jan 2026 - Phase 2 EGFR inhibitor shows strong efficacy and safety; key 2025 data and regulatory updates ahead.BDTX
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - BDTX-1535 shows promise in NSCLC and GBM, with pivotal data and regulatory milestones ahead.BDTX
24th Annual Needham Virtual Healthcare Conference27 Dec 2025 - Lead oral therapy 1535 targets broad NCMs in NSCLC, with pivotal data and FDA update in Q4 2024.BDTX
Stifel 2025 Virtual Targeted Oncology Forum23 Dec 2025 - Shelf registration allows up to $500M in offerings, with $150M at-the-market via Jefferies.BDTX
Registration Filing16 Dec 2025